- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NLS Pharmaceutics und Kadimastem streben Fusion im Januar an | - | Investing.com Deutsch | ||
| NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | NLS Pharmaceutics and Kadimastem eye January merger | 3 | Investing.com | ||
| Do | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment | 185 | ACCESSWIRE | This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS... ► Artikel lesen | |
| Mi | NLSP-Aktie erreicht 52-Wochen-Tief bei 1,74 US-Dollar | - | Investing.com Deutsch | ||
| Di | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12. | NLSP stock touches 52-week low at $1.81 amid market challenges | 1 | Investing.com | ||
| 11.12. | NLSP-Aktie erreicht 52-Wochen-Tief bei 1,81 US-Dollar | 3 | Investing.com Deutsch | ||
| 11.12. | NLS Pharmaceutics advances in narcolepsy treatment research | 4 | Investing.com | ||
| 11.12. | NLS Pharmaceutics AG: NLS Pharmaceutics CEO Issues Letter to Shareholders | 197 | ACCESSWIRE | ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... ► Artikel lesen | |
| 04.12. | NLS Pharmaceutics announces pricing of private placement of up to $1M | 2 | Seeking Alpha | ||
| 04.12. | NLS Pharmaceutics legt Bedingungen für private Platzierung über 1 Million US-Dollar fest | 3 | Investing.com Deutsch | ||
| 04.12. | NLS Pharmaceutics sets terms for $1M private placement | 2 | Investing.com | ||
| 03.12. | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | 548 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| 03.12. | NLS Pharmaceutics präsentiert vielversprechende präklinische Daten | 1 | Investing.com Deutsch | ||
| 03.12. | NLS Pharmaceutics reveals promising preclinical data | 1 | Investing.com | ||
| 03.12. | NLS Pharmaceutics AG: NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders | 39 | ACCESSWIRE | ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential... ► Artikel lesen | |
| 03.12. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.11. | NLS Pharmaceutics AG: NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders | 200 | ACCESSWIRE | ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... ► Artikel lesen | |
| 12.11. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11. | NLS Pharmaceutics and Kadimastem stocks soar following merger agreement | 1 | Pharmaceutical Technology |
Seite:
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,260 | -15,44 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
NLS PHARMACEUTICS LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -18,07 % bei einem Aktienkurs von 1,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NLS PHARMACEUTICS LTD finden Sie auf Wallstreet Online.
